Centrum Medyczne

Piotrkow Trybunalski 97 300

0 studies enrolling now · 2 studies all time

What they study most

Bladder Cancer, Crohn Disease

Studies at this site

• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) — Running, not enrolling